Lupin Pharmaceuticals (LPI), a US subsidiary of India-based Lupin, has launched its generic Rabeprazole Sodium delayed-release tablets, 20mg.
Earlier, the company had received final approval from the US Food and Drug Administration (FDA) for the same.
Rabeprazole Sodium delayed-release tablets, 20mg, are the generic equivalent of Eisai's Aciphex delayed-release tablets, 20mg, and are indicated for the treatment of Gastroesophageal reflux disease (GERD).
Lupin, which develops and produces a wide range of branded and generic formulations and APIs globally, is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space.
The company also holds global leadership positions in the Anti-TB and Cephalosporin segment.
For the year ended March 2013, Lupin's consolidated turnover and profit after tax were $1.74bn and $242m respectively.
Lupin Pharmaceuticals is dedicated in delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies.
